{"DataElement":{"publicId":"2969591","version":"1","preferredName":"Breast Carcinoma Stage Grouping Type","preferredDefinition":"A description of the breast carcinoma stage.","longName":"2969576v1.0:2969585v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2969576","version":"1","preferredName":"Breast Carcinoma Stage Grouping","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"BCSTAG_GRUP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC74FCE-29BB-F82B-E040-BB89AD43303E","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-12-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for \"breast carcinoma\".  No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2969585","version":"1","preferredName":"Breast Carcinoma Stage Grouping Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._Type; a subdivision of a particular kind of thing.","longName":"BC_STAGE","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"In situ","valueDescription":"In situ","ValueMeaning":{"publicId":"2558929","version":"1","preferredName":"In situ","longName":"2558929","preferredDefinition":"in the natural or normal place, confined to the site of origin without invasion of neighboring tissues. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Situ","conceptCode":"C14160","definition":"In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B33E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2009-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8796F3C7-D184-DF84-E040-BB89AD434560","beginDate":"2009-12-15","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"},{"value":"I","valueDescription":"T1 NO MO","ValueMeaning":{"publicId":"3351861","version":"1","preferredName":"T1 NO MO","longName":"3351861","preferredDefinition":"I includes:T1, NO, MO. T1: Tumor 2.0 cm or less in greatest dimension. T1mic: Microinvasion 0.1 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th Ed.)-2003","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-19F7-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1A10-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"II","valueDescription":"T0 N1 M0; T1 N1 M0 or T2, N0 M0; T2 N1 M0 or T3 N0 M0","ValueMeaning":{"publicId":"3351862","version":"1","preferredName":"T0 N1 M0; T1 N1 M0 or T2, N0 M0; T2 N1 M0 or T3 N0 M0","longName":"3351862","preferredDefinition":"II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, MO); (T3,NO,MO). T0: No evidence of primary tumor. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension. T3: Tumor more than 5.0 cm in greatest dimension. N1: Metastasis to movable ipsilateral axillary lymph node(s). M0: No distant metastasis. (AJCC 6th Ed.) - 2003","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-1A1A-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1A33-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"T0 N2 M0; T1 N2 M0; T2 N2 M0 or T3 N1 M0; T3 N2 M0","ValueMeaning":{"publicId":"3351863","version":"1","preferredName":"T0 N2 M0; T1 N2 M0; T2 N2 M0 or T3 N1 M0; T3 N2 M0","longName":"3351863","preferredDefinition":"IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-1A3D-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1A56-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"T4 Nany M0, Tany N3 M0, inflammatory","ValueMeaning":{"publicId":"3351864","version":"1","preferredName":"T4 Nany M0, Tany N3 M0, inflammatory","longName":"3351864","preferredDefinition":"IIIB includes: (T4, any N, M0). T4: Tumor of any size with direct extension to (a) chest wall or (b) skin. N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis. N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No distant metastasis. (AJCC 6th Ed.) - 2003","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-1A60-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1A79-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"IV","valueDescription":"Tany Nany M1","ValueMeaning":{"publicId":"3351865","version":"1","preferredName":"Tany Nany M1","longName":"3351865","preferredDefinition":"Any T, Any N, M1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-1A83-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1A9C-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B66D065F-1AA6-4C96-E040-BB89AD437AF5","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","deletedIndicator":"No"},{"value":"Invasive Carcinoma","valueDescription":"Invasive Carcinoma","ValueMeaning":{"publicId":"7639506","version":"1","preferredName":"Invasive Carcinoma","longName":"7639506","preferredDefinition":"Invasive Carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C080CD78-9660-6F90-E053-4EBD850A2FEE","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C080CD78-9679-6F90-E053-4EBD850A2FEE","beginDate":"2021-04-21","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3061602","version":"1","preferredName":"Breast Carcinoma Stage Grouping Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR):Type; a subdivision of a particular kind of thing.","longName":"C4872:C38027:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84902434-A446-9A05-E040-BB89AD431C3A","latestVersionIndicator":"Yes","beginDate":"2010-04-19","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-04-19","modifiedBy":"ONEDATA","dateModified":"2010-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC74FCE-2A74-F82B-E040-BB89AD43303E","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-12-15","modifiedBy":"ZHANGWE","dateModified":"2021-04-21","changeDescription":".Updated def for \"breast carcinoma\".  No version needed. AK 9/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964891","version":"1","longName":"2020r1: Breast Cancer Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"bc_base_diag_stg_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"BRST_CA_STG_GR_TP","type":"DCP Alt Name","context":"DCP"}],"ReferenceDocuments":[{"name":"What was the stage of breast","type":"Preferred Question Text","description":"What was the stage of breast cancer?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2969591","type":"BRIDG Mapping Path","description":"PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalInterpretation.value WHERE PerformedDiagnosis.value = \"breast cancer\" AND AssessedResultRelaitonship.typeCode = \"staging\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AC74FCE-2B4D-F82B-E040-BB89AD43303E","latestVersionIndicator":"Yes","beginDate":"2009-12-15","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-12-15","modifiedBy":"TITARENI","dateModified":"2022-01-26","changeDescription":".Updated def for \"breast carcinoma\". No version needed. AK 9/18/12 System generated def displayed as alt def. 2021-6-21 ak","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}